|
|
|
|
|
Foster City, CA, Hangzhou and Shanghai, China, Aug 10, 2021 - (ACN Newswire) - Apollomics Inc., an innovative biopharmaceutical company committed to the discovery and development of mono- and combination oncology therapies, today announced the successful dosing of the first patient in a Phase I clinical study of APL-102 in patients with advanced solid tumors. The Phase I trial is designed to assess the safety, tolerability and pharmacokinetics of APL-102 delivered via an oral capsule.
"APL-102 is an internally discovered and developed tyrosine kinase inhibitor targeting multiple oncogenic drivers, and we are excited about advancing it for clinical testing to explore its potential for treating a number of solid tumors;" said Guo-Liang Yu, PhD, Co-Founder, Chairman and Chief Executive Officer. "APL-102 is the first of several novel assets planned for clinical development to further expand Apollomics' clinical pipeline in oncology."
About APL-102
APL-102 is an oral, small molecule multi kinase inhibitor (MTKi) targeting several key oncogenic drivers. APL-102 inhibits several receptor tyrosine kinases (RTKs), including: angiogenesis via vascular endothelial growth factor receptors (VEGFRs), mitogen-activated protein kinase (MAPK) pathway via B-RAF and C-RAF; and colony stimulating factor 1 receptor (CSF1R).
Preclinical studies have demonstrated broad and potent antitumor activity in patient-derived xenograft mouse models of liver, breast, colorectal, gastric, esophageal and lung cancers. APL-102 has also shown favorable preclinical pharmacokinetic (PK) and safety profiles with no serious off-target activity observed. APL-102 has the potential to be used as a single agent or in combination with other oncology agents.
Apollomics retains worldwide rights to APL-102.
About Apollomics Inc.
Apollomics Inc. is an innovative biopharmaceutical company committed to the discovery and development of monotherapies and combination therapies of tumor-targeting agents and immuno-oncology agents. The Company's product pipeline has several programs at different stages of development, including novel, humanized monoclonal antibodies that restore the body's immune system to recognize and kill cancer cells, and targeted therapies against uncontrolled growth signaling pathways. Apollomics has operating entities in Foster City, Ca., USA, Hangzhou and Shanghai, China. For more information, please visit www.apollomicsinc.com.
Contact information of Apollomics:
Investor Contact:
Wilson W. Cheung
Chief Financial Officer
(650) 209-4436
wcheung@apollomicsinc.com
U.S. Media Contact:
Remy Bernarda
Corporate Communications
(415) 203-6386
remy.bernarda@apollomicsinc.com
China Media Contact:
Porda Havas International Finance Communications Group
Kelly Fung
General Manager
(852) 3150 6763
kelly.fung@pordahavas.com
Phoenix Fung
Vice President
(852) 3150 6773
phoenix.fung@pordahavas.com
Topic: Press release summary
Source: Apollomics, Inc.
Sectors: Clinical Trials
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| Apollomics, Inc. |
| Mar 30, 2023 20:29 HKT/SGT |
|
Apollomics, a Company Developing Novel Oncology Therapies to Address Difficult-to-Treat Cancers, Announces Closing of Business Combination and Listing on Nasdaq |
| July 26, 2022 09:17 HKT/SGT |
|
Apollomics Inc. Expands Leadership Team with Appointment of Jane Wang, PhD as Chief Scientific Officer |
| Jan 12, 2022 09:25 HKT/SGT |
|
Apollomics Inc. to Host Virtual Investor Events on Wednesday, January 26, 2022 and Thursday, January 27, 2022 |
| Jan 4, 2022 10:10 HKT/SGT |
|
Apollomics Inc. Announces CEO Guo-Liang Yu, PhD Appointed as Chairman of the Board for the BayHelix Group |
| Nov 22, 2021 10:40 HKT/SGT |
|
Apollomics Inc. Doses First Patient in Phase 3 Clinical Trial with APL-106 (Uproleselan Injection) in Chinese Patients with Relapsed/Refractory Acute Myeloid Leukemia |
| Oct 1, 2021 10:00 HKT/SGT |
|
Edison Oncology and Apollomics Announce Treatment of First Patient by EO1001 (APL-122) in a Phase I/IIa Clinical Trial |
| May 20, 2021 13:36 HKT/SGT |
|
APOLLOMICS INC. ANNOUNCES OFFICIAL OPENING OF SHANGHAI BRANCH |
| Mar 9, 2021 10:35 HKT/SGT |
|
Apollomics, Inc. Appoints Seasoned Healthcare Executive K. Peony Yu, M.D., as Chief Medical Officer |
| Mar 4, 2021 11:30 HKT/SGT |
|
Apollomics, Inc Announces Enrollment of First Patient in Phase 1 Clinical Trial of APL-106 (uproleselan injection) in China |
| Feb 12, 2021 13:00 HKT/SGT |
|
Apollomics, Inc. Licenses a Targeted, Active Checkpoint Control Immunotherapy for Greater China and South Africa |
| More news >> |
 |
|
|
|
